Duration: 60 Minutes


Purchase Options: *

Learn More

The United States Food and Drug Administration (FDA) recently expressed deep concerns over the growing epidemic of opioid dependence, overuse and abuse on families and communities.

Opioids as prescription drugs are used to reduce chronic pain. Opioids offer both great benefits and also serious risks, potentially causing serious harm (addiction, overdose and even death) when misused or abused.

This seminar is intended to help industry and professionals to better understand FDA roles and regulation governing controlled substances (opioids) used for pain management. This seminar is also intended to help industry get better familiar with FDA’s recent activity and regulatory expectations for drugs (opioids) including generic opioids and recent approvals for pain management.

In this 60-min presentation, the speaker will guide you through the details of FDA roles, regulations, generic opioids and recent FDA approvals for chronic pain management.

Areas Covered in the Session :

  • FDA Laws and Regulations
  • Definitions
  • Learn About Controlled Substances
  • Regulation of Abuse-Deterrent Opioid Medications
  • Opioid Misuse & Abuse
  • Prevention of Opioid Abuse and Appropriate Pain Management
  • New Labeling Requirements
  • FDA Approved Generic Opioids
  • Recent FDA Approvals for Pain Management Drugs
  • Best Practices

Who Should Attend:

  • Regulatory Affairs Departments
  • Research and Development Departments
  • Clinical Affairs Departments
  • Quality Departments
  • Marketing Departments
  • Senior Management
  • Contractors and Subcontractors
  • Medical Doctors and Healthcare Professionals
  • Consultants
  • Everyone who is interested in the topic

Course Director: DR. DAVID LIM ‎

Dr. David Lim, Ph.D., RAC, ASQ-CQA. Dr. Lim is President and Principal of Regulatory Doctor (www.RegulatoryDoctor.us). As a leading industry speaker, Dr. Lim frequently presents global regulatory and quality compliance topics in various forums and meetings. Recently, Dr. Lim developed 510(k) templates ready for use compliant with e-Copy and RTA policy. In addition, Dr. Lim developed FDA inspection checklists for drug and medical device manufacturers based on his analysis of FDA inspectional observations cited in 483s for the past eight years. Dr. Lim provides his feedback to regulatory agency (e.g., US FDA) through public comments and also served as a panel member during the FDA’s transparency public meeting in 2009.

Dr. Lim contributes to the Regulatory Affairs Professional Society (RAPS) as an author and speaker. Dr. Lim leads and directs all research projects including pharmacovigilance, medical device reporting, recalls and patient safety signals being conducted at the Regulatory Doctor. Dr. Lim currently serves as a member of the Advisory Board for Inspection Insider published by FDA News.